Search Results - "Starovoĭtova, M N"

Unusual case of development of induced scleroderma with general fibrosis, ulcer-necrotic changes in the limbs and calcinosis by Guseva, N G, Starovoĭtova, M N

Get full text

The Use of “Acellbia”—A Biosimilar of Rituximab in Systemic Sclerosis by Ananyeva, L. P., Garzanova, L. A., Desinova, O. V., Shayakhmetova, R. U., Starovoitova, M. N., Koneva, O. A., Ovsyannikova, O. B., Glukhova, S. I., Nasonov, E. L.

“…The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a disease-modifying effect. This…”
Get full text

Fibrosing arthropathy in juvenile scleroderma by Dibrov, D. A., Starovoitova, M. N., Desinova, O. V.

“…The group of scleroderma diseases includes a number of clinical entities, the main symptom of which is skin tightening. Scleroderma is a prominent example of…”
Get full text

Renal function during long-term therapy with rituximab in patients with systemic sclerosis by Starovoitova, M. N., Desinova, O. V., Ananyeva, L. P., Koneva, O. A., Garzanova, L. A., Ovsyannikova, O. B., Shayakhmetova, R. U.

“…   In systemic sclersis (SSc), different types of renal involvement occur. Their severity can range from asymptomatic deterioration of renal function to…”
Get full text

Therapy for digital ulcers in patients with systemic scleroderma by Starovoitova, M. N., Desinova, O. V.

“…As of now, there are several pharmacological directions in the treatment and prevention of Raynaud’s syndrome and digital ulcers, including various vasoactive…”
Get full text

Risk factors for low bone mineral density in postmenopausal women with systemic sclerosis by Efremova, A. O., Toroptsova, N. V., Dobrovolskaya, O. V., Starovoitova, M. N., Desinova, O. V., Nikitinskaya, O. A.

“…Aim of the research – to determine the frequency of osteoporosis (OP) and to identify risk factors for a decrease in bone mineral density (BMD) in…”
Get full text

Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 2. Safety and complications by Ovsyannikova, O. B., Ananyeva, L. P., Koneva, O. A., Garzanova, L. A., Desinova, O. V., Shayakhmetova, R. U., Starovoitova, M. N., Lila, A. M.

“…Autologous hematopoietic stem cell transplantation (auto-HSCT) is presently the only disease-modifying strategy for the treatment of systemic sclerosis (SSs)…”
Get full text

Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 1. Clinical aspects by Ovsyannikova, O. B., Ananyeva, L. P., Koneva, O. A., Garzanova, L. A., Shayakhmetova, R. U., Desinova, O. V., Starovoitova, M. N., Lila, A. M.

“…Diffuse cutaneous systemic sclerosis (SSc) characterized by an acute, rapidly progressive course and severe damage to the internal organs has an unfavorable…”
Get full text

Clinical and laboratory characteristics of patients with systemic sclerosis positive for anti-ribonucleoprotein antibodies by Shayakhmetova, R. U., Ananyeva, L. P., Koneva, O. A., Starovoitova, M. N., Desinova, O. V., Ovsyannikova, O. B., Garzanova, L. A.

“…Among the patients fulfilling the criteria for systemic sclerosis (SS), there is a subgroup without SS-specific antinuclear antibodies, but positive for…”
Get full text

Immunological features in anti-U1-ribonucleoprotein antibody positive patients with systemic scleroderma by Shayakhmetova, R. U., Ananyeva, L. P., Koneva, O. A., Starovoitova, M. N, Desinova, O. V., Ovsyannikova, O. B., Garzanova, L. A.

“…In anti-U1-ribonucleoprotein (anti-U1-RNP) antibody positive patients with systemic scleroderma (SSD), the clinical picture and course of the disease have…”
Get full text

Comparative characteristics of the main phenotypes of systemic sclerosis by Shayakhmetova, R. U., Ananyeva, L. P., Starovoitova, M. N., Desinova, O. V., Koneva, O. A., Ovsyannikova, O. B., Garzanova, L. A., Cherkasova, M. V., Alekperov, R. T.

“…Various clinical and immunological phenotypes of systemic sclerosis (SS) differ in the frequency and severity of manifestations of the disease, the progression…”
Get full text

Effect of rituximab on the manifestations of activity and pulmonary function in patients with systemic sclerosis: one-year follow-up evaluation by Ananyeva, L. P., Koneva, O. A., Desinova, O. V., Garzanova, L. A., Glukhova, S. I., Starovoitova, M. N., Ovsyannikova, O. B., Volkov, A. V., Aleksankin, A. P., Nasonov, E. L.

“…The choice of drugs for the treatment of interstitial lung disease (ILD) associated with systemic sclerosis (SS) is currently very limited. Data from a number…”
Get full text

Scleromyxedema concurrent with dermatomyositis and paraproteinemia: A case report by Starovoitova, M. N., Desinova, O. V., Guseva, N. G.

“…The paper describes the case of a female patient who had at least three diseases: scleromyxedema, dermatomyositis/polymyositis (DM/PM), and paraproteinemia…”
Get full text

THE MAIN RESULTS OF COOPERATION BETWEEN THE V.A. NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY AND RESEARCH CENTERS OF EUROPE WITHIN THE EUSTAR (EULAR SCLERODERMA TRIALS AND RESEARCH GROUP) IN SYSTEMIC SCLEROSIS by Ananyeva, L. P., Starovoitova, M. N., Shabanova, S. Sh

“…The major goals of the EUSTAR (EULAR Scleroderma Trials And Research group) are to coordinate and centralize systemic sclerosis (SS) researches in Europe, to…”
Get full text

FAS APOPTOTIC GENE POLYMORPHISM (-670A/G) IS ASSOCIATED WITH CLINICAL PHENOTYPES OF SYSTEMIC SCLEROSIS IN A RUSSIAN POPULATION: A PILOT STUDY by Krylov, M. Yu, Ananyeva, L. P., Koneva, O. A., Starovoitova, M. N., Samarkina, E. Yu, Desinova, O. V., Ovsyannikova, O. B., Aleksandrova, E. N., Novikov, A. A., Guseva, I. A.

“…The FAS antigen (Apo-1/CD95) is a key molecule of apoptosis in most cell types, including activated immune cells and fibroblasts. The FAS gene promoter region…”
Get full text

Profile of autoantibodies in systemic sclerosis by Starovoitova, M. N., Desinova, O. V., Koneva, O. A., Ovsyannikova, O. B., Alekperov, R. T., Cherkasova, M. V., Aleksandrova, E. N., Ananyeva, L. P.

“…Objective: to estimate frequency of autoantibodies in a cohort of Russian patients with systemic sclerosis (SS) and to investigate clinical associations of…”
Get full text

ASSESSMENT OF THE SENSITIVITY OF NEW CRITERIA FOR SYSTEMIC SCLEROSIS IN RUSSIAN PATIENT POPULATION by Koneva, O. A., Ovsyannikova, O. B., Starovoitova, M. N., Cheremukhina, E. O., Aleksandrova, E. N., Ananyeva, L. P.

“…Systemic sclerosis (SS) is a progressive connective tissue disease, the prognosis of which largely depends on the time of adequate therapy initiation. Low…”
Get full text

RITUXIMAB TREATMENT FOR INTERSTITIAL LUNG INJURY IN SCLERODERMA SYSTEMATICA by Ananieva, Lidia Petrovna, Desinova, O V, Koneva, O A, Starovoitova, M N, Yutkina, N N, Volkov, A V, Ovsyannikova, O B, Aleksankin, A P, Aleksandrova, E N, Novikov, A A, Nasonov, E L

“…Objective: to study the efficiency and tolerance of rituximab (RTM) treatment in patients with scleroderma systematica (SDS) with interstitial lung injury…”
Get full text

Differential diagnosis of myopathic syndrome in dermatomyositis/polymyositis and progressive muscular dystrophies (description of a case) by Olga Alekseevna Antelava, M N Starovoitova, O V Desinova, S S Nikitin, E L Nasonov

Get full text

COMPLEX THERAPY FOR VASCULAR DISORDERS IN PATIENTS WITH SCLERODERMA SYSTEMATICA by M N Starovoitova, O V Desinova, A V Volkov

“…Scleroderma systematica (SDS) is a disease in which vascular diseases underlie the pathogenesis and presented by diverse clinical manifestations. Raynaud's…”
Get full text